Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of entacapone (ENT).
Background: OPC proved to be effective in treating end-of-dose MF in PD patients [1,2]. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of patients treated in real-world conditions [3].
Method: OPTIPARK was a prospective, open-label, single-arm trial conducted in Germany and the UK. Patients with MF received OPC 50 mg in addition to current antiparkinsonian treatment. Primary efficacy 3-month endpoint was Clinician’s-Global-Impression-of-Change (CGI-C). Secondary efficacy endpoints included Patient’s-CGI-C (PGI-C), 8-item PD-Questionnaire (PDQ-8), Unified PD Rating Scale (UPDRS) and Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). This post-hoc analysis evaluated the influence of baseline use of ENT in patients who completed the study for each outcome.
Results: Overall, 393 (82.4%) patients completed the 3-month endpoint (completers-set, Table 1). Of these, patients NOT using ENT at baseline experienced greater improvements on CGI-C and PGI-C, UPDRS-II and III, quality of life (PDQ-8) and non-motor symptoms (NMSS), when compared to patients using ENT (and switched) at baseline (Table 2, Table 3). Similar incidence of TEAEs considered at least possibly related to OPC were reported for both subgroups (Table 3).
Conclusion: Overall, these findings indicate that patients not using ENT at baseline (representative of recent fluctuators) may have an added benefit from using OPC 50 mg as adjunctive therapy to levodopa.
References: 1. Ferreira et al., Lancet Neurology 2016; 15(2):154-165. 2. Lees et al., JAMA Neurol. 2017; 74(2):197-206. 3. Reichmann et al., Transl Neurodegener. 2020;9(1):9
To cite this abstract in AMA style:
W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva. Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-according-to-baseline-use-of-entacapone-findings-from-the-real-world-optipark-study/. Accessed May 15, 2025.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-according-to-baseline-use-of-entacapone-findings-from-the-real-world-optipark-study/